Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions.
The substrate of matrix metalloproteinase 11 (MMP11) remains unknown. We have recently shown that MMP11 is a negative regulator of adipogenesis, able to reduce and even to revert mature adipocyte differentiation. Here, we have used mouse 3T3L1 cells and human U87MG and SaOS cells to show that MMP11 cleaves the native alpha3 chain of collagen VI, which is an adipocyte-related extracellular matrix component. It is known that extracellular proteolytic processing of this chain is required for correct collagen VI folding. Interestingly, MMP11-deficient fat tissue is less cohesive and exhibits collagen VI alteration, dramatic adipocyte plasma and basement membrane abnormalities and lipid leakage. MMP11 is thus required for correct collagen VI folding and therefore for fat tissue cohesion and adipocyte function. Both MMP11 and collagen VI favor tumor progression. Similar spatio-temporal overexpression at the adipocyte-cancer cell interface has been reported for the two proteins. MMP11-dependent collagen VI processing might therefore be expected to occur during malignancy. Accordingly, collagen VI no longer delineates adipocytes located at the invasive front of breast carcinomas. In conclusion, the native alpha3 chain of collagen VI constitutes a specific MMP11 substrate. This MMP11 collagenolytic activity is functional in fat tissue ontogenesis as well as during cancer invasive steps.
Motrescu
E R
ER
1Departement de Biologie du Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR 7104, INSERM U596, Université Louis Pasteur, Illkirch Cedex, France.
Blaise
S
S
Etique
N
N
Messaddeq
N
N
Chenard
M-P
MP
Stoll
I
I
Tomasetto
C
C
Rio
M-C
MC
D041721:3T3-L1 Cells; D017667:Adipocytes / Q000378:metabolism / Q000473:pathology / Q000502:physiology / Q000648:ultrastructure; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism / Q000502:physiology*; D024142:Collagen Type VI / Q000378:metabolism / Q000502:physiology*; D004622:Embryo, Mammalian / Q000166:cytology / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism / Q000473:pathology / Q000502:physiology* / Q000648:ultrastructure; D016326:Extracellular Matrix Proteins / Q000378:metabolism / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology / Q000502:physiology; D005909:Glioblastoma / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D053507:Matrix Metalloproteinase 11 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D012516:Osteosarcoma / Q000378:metabolism / Q000473:pathology; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D016622:Silver Staining
D024142:Collagen Type VI; D016326:Extracellular Matrix Proteins; D007004:Hypoglycemic Agents; D007328:Insulin; D011994:Recombinant Proteins; D003094:Collagen; D053507:Matrix Metalloproteinase 11